- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation
We sat down with Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.
Welcome to Not So Different, a podcast from The Center for Biosimilars®. I’m your host, Assistant Editor Skylar Jeremias.
A recently published opinion piece from 2 executives of Sandoz and Boehringer Ingelheim argued that misinformation is weakening patient and physician trust in biosimilars, preventing access to these lower-cost biologics, and slowing their uptake in the United States. The authors also called for changes in standard biosimilar terminology that they say misleads the public about the safety and use of these products.
We sat down with an author of the opinion piece, Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.
To learn more about the opinion piece McCabe co-authored, click here.
To learn more about Boehringer Ingelheim, visit boehringer-ingelheim.com.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
